The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Real-world outcomes of second-line chemotherapy on advanced biliary tract and gallbladder cancers
Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides an update on the results of a multicenter retrospective population-based cohort study evaluating the impact of real-world second-line chemotherapy on survival in patients with advanced biliary tract and gallbladder cancers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
